Overview

Flurbiprofen Tape for Treatment of Chronic Low Back Pain

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this trial is to evaluate the analgesic efficacy and safety of flurbiprofen tape for chronic low back pain (lasting greater than 3 months).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Teikoku Pharma USA
Teikoku Pharma USA, Inc.
Treatments:
Flurbiprofen
Criteria
Inclusion Criteria:

- male or female 18 to 80 years;

- signed an informed consent;

- daily LBP below the 12th thoracic vertebra of greater than 3 months' duration;

- able to ambulate at least 100 meters;

- in stable general health with laboratory values within normal limits

- no evidence of drug abuse or residual opiates; determined by urine drug screening;

- diagnosis of chronic LBP verified by medical records;

- female patients must be postmenopausal (defined as 1 year without menses), physically
incapable of becoming pregnant, or using an acceptable birth control method.
Non-postmenopausal patients must have confirmation of a negative urine pregnancy test;

- must read and speak English;

- must be reliable and mentally competent to complete study measurements;

- must be available for the study visits and telephone checks from study entry to study
completion.

- male patients must use an acceptable method of birth control with their female
partners;

- rates their pain at 3 or higher on an 11-point Categorical Pain Scale for LBP over the
prior week (7 days) of Visit 1.

- over the last 3 days of the Baseline Phase, had a computed average pain score of 4 or
greater on an 11-point Categorical Pain Scale

- discontinued the use of any topical pain medications, salves, anticonvulsants, oral
NSAIDs, muscle relaxants, opioids, or anti-inflammatory steroids during the Baseline
Phase. Acetaminophen, at a dose of ≤ 1000 mg per day is acceptable;

- able to discontinue the use of therapy defined as ice, heat, chiropractic care,
physical therapy, acupuncture and acupressure on their lower back area during the
Baseline Phase.

Exclusion Criteria:

- open skin lesion within the painful area;

- experiencing LBP for less than 3 months;

- undergone back surgery within the past 3 months or has plans for back surgery within
30 days post-study;

- participated in clinical treatment studies within 30 days of study entry;

- chronic back pain which is due to fibromyalgia or connective tissue disorder (lupus,
rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, etc.);

- LBP due to malignancy, vertebral fracture, or infection;

- used opioids (including low potency/low dose opioid combinations and tramadol) more
than 2 times per week within 30 days of study entry. Opioids and tramadol must not
have been taken at least 4 days prior to study entry;

- had injection therapy within 30 days of study entry, including corticosteroids;

- a clinically significant psychiatric disorder (severe depression, other Axis I or Axis
II disorders as defined in the Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV);

- taking lithium, furosemide, and/or thiazides;

- considered unreliable as to medication compliance (if any medication other than 1000
mg or less of acetaminophen a day was taken for any type of pain, the patient was
discontinued) or adherence to scheduled appointments as determined by the
investigators;

- a prior history of GI bleeds/ulcers or clinically significant liver/kidney disease;

- known hypersensitivity to flurbiprofen or other NSAIDs;

- has a coagulation disorder or is taking warfarin or other anticoagulants (aspirin at a
dose of [≤ 81 mg] is acceptable);

- clinically significant fluid retention, cardiovascular disease (CVD), hypertension, or
heart failure;

- had coronary artery bypass graft surgery (CABG), cardiovascular thrombotic event,
myocardial infarction (MI) and/or stroke within 1 year of Visit 1;

- had unresolved litigation related to back injury or other pain complaints; settled
disability claims/payments (Worker's Compensation, state/federal/private disability
plans) were allowed.